Rhumbline Advisers Bicycle Therapeutics PLC Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Rhumbline Advisers holds 1,027 shares of BCYC stock, worth $23,292. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,027
Previous 639
60.72%
Holding current value
$23,292
Previous $15,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BCYC
# of Institutions
111Shares Held
40.7MCall Options Held
3.4KPut Options Held
12.4K-
Baker Bros. Advisors LP New York, NY9.4MShares$213 Million2.53% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.49MShares$79.2 Million2.32% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.25MShares$51.1 Million0.69% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.12MShares$48.1 Million6.34% of portfolio
-
Armistice Capital, LLC New York, NY1.97MShares$44.7 Million0.52% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $673M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...